CADD is a cutting-edge computational method used to locate and develop a promising lead in the drug discovery process. Molecular modelling, molecular design, computational chemistry, and rational drug design are all components of computer-aided drug design. To maximise discovered leads, CADD is being employed. Both in academic communities and the pharmaceutical companies, CADD approaches are becoming more well-liked and respected. Time is saved, and the CADD technique is quick and economical. The four steps of the CADD method are as follows: (1) use a virtual screening (VS) protocol to screen a small molecule library against the target to find hits or leads, (2) examine the specificity of the selected hits from VS using molecular docking in the active site of other recognized targets, and (3) predict ADMET properties of the selected hit using in silico techniques and the most promising hits are referred to as leads and step four assists in optimizing the leads by creating better compounds for synthesis and testing. Structure-based and ligand-based drug design are the two categories into which CADD approaches are divided depending on the availability of the target protein's 3D structure (SBDD and LBDD). The pharmacological target's 3D structure is necessary for SBDD. The target structure can be obtained in one of two ways: (1) by downloading it from the Protein Data Bank (PDB) if the protein structure has been solved by crystallography and (2) employ molecular modeling (a bioinformatics technique) to forecast the structure if the protein structure cannot be determined.
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : A NAMs-compatible mechanopharmacological model of drug penetration in the urinary bladder
Kunal Sharma, Swisss Federal Institute of Technology Lausanne, Switzerland
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Integrated Raman, SERS and computational approaches for the study of bioactive molecules in pharmaceutical chemistry
Maria Cristina Gamberini, University of Modena and Reggio Emilia, Italy
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada